Gilteritinib + Midostaurin
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
Trial Timeline
Dec 20, 2019 → Jun 1, 2033
NCT ID
NCT04027309About Gilteritinib + Midostaurin
Gilteritinib + Midostaurin is a phase 3 stage product being developed by Astellas Pharma for Acute Myeloid Leukemia. The current trial status is active. This product is registered under clinical trial identifier NCT04027309. Target conditions include Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04027309 | Phase 3 | Active |
Competing Products
20 competing products in Acute Myeloid Leukemia